Image-Guided Biopsies to Identify Mechanisms of Resistance in Patients With Metastatic Castration Resistant Prostate Cancer Treated With 177Lu-PSMA Radioligand Therapy
NCT05398302
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
This clinical trial studies mechanisms of resistance to 177-lutetium prostate specific membrane antigen (177Lu-PSMA) radioligand therapy using image-guided biopsies in patients with castrate-resistant prostate cancer that had spread to other places in the body (metastatic). Diagnostic procedures, such as image guided biopsies, may help in learning how well 177Lu-PSMA works to kill tumor cells and allow doctors to plan better treatment.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Castration-Resistant Prostate Carcinoma
- Metastatic Prostate Carcinoma
- Stage IV Prostate Cancer American Joint Committee on Cancer (AJCC) v8
- Stage IVA Prostate Cancer AJCC v8
- Stage IVB Prostate Cancer AJCC v8
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- Any age
- Sex
- Male
- Healthy volunteers
- Not accepted
- Sponsor
- Jonsson Comprehensive Cancer Center
- Last updated on ClinicalTrials.gov
- June 15, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- UCLA / Jonsson Comprehensive Cancer Center · Los Angeles, CA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.